Let's discuss orforglipron — Eli Lilly's oral non-peptide GLP-1 receptor agonist currently in Phase 3 (ATTAIN program). This is a fundamentally different molecule from oral semaglutide. Semaglutide is a peptide that requires the SNAC absorption enhancer and must be taken fasting with minimal water. Orforglipron is a small molecule — no fasting requirement, no absorption enhancer, and potentially much cheaper to manufacture.
The Phase 2 data were published by Wharton et al. in the NEJM[1]:
Design: Phase 2, dose-finding. N = 272 adults with BMI >= 30 (or >= 27 with comorbidity), without diabetes. Multiple dose cohorts (12, 24, 36, 45 mg daily). 36 weeks.
Results (treatment estimand, 36 weeks):
- Placebo: -2.0%
- 12 mg: -8.6%
- 24 mg: -12.6%
- 36 mg: -12.4%
- 45 mg: -14.7%
At 36 weeks and still declining. Not as dramatic as retatrutide, but competitive with injectable semaglutide at a similar timepoint. And it's a pill.
The ATTAIN Phase 3 program includes trials in obesity (ATTAIN-1), obesity with T2D (ATTAIN-2), and CV outcomes (ATTAIN-4). This is a full development program targeting FDA approval.
[1] Wharton S, et al. N Engl J Med. 2023;389(10):877-888.
The manufacturing story is what excites me most. Oral semaglutide (Rybelsus) requires the SNAC enhancer, has ~1% bioavailability, and needs 14 mg oral to approximate 0.5 mg injectable. That's incredibly wasteful from a manufacturing standpoint and limits cost reduction potential.
Orforglipron is a small molecule made by standard pharmaceutical chemistry — no peptide synthesis, no complex formulation. If it works, it could break the supply and cost bottleneck that has plagued GLP-1 RAs. Lilly has said it expects manufacturing costs to be "substantially lower" than injectable GLP-1 RAs.
Of course, "if it works" is doing a lot of heavy lifting. Phase 2 was small (n=272) and short (36 weeks). We need Phase 3 to confirm efficacy, assess longer-term safety, and understand the full dose-response. ATTAIN-1 results are expected in mid-2025.
Let me do a cross-compound comparison at similar timepoints. At 36-40 weeks:
- Orforglipron 45 mg oral daily: -14.7% (Phase 2, 36 wks)
- Semaglutide 2.4 mg SC weekly: ~-12.5% (STEP 1 at week 36 extrapolated from the published curve)[2]
- Oral semaglutide 50 mg daily: -15.1% (OASIS-1, 68 weeks, though not directly comparable)[3]
- Tirzepatide 15 mg SC weekly: ~-16% (SURMOUNT-1 at week 36, extrapolated)
Orforglipron is competitive but likely won't match tirzepatide's dual-agonist efficacy. Its advantage is the oral route, small molecule manufacturing, and potential for lower cost. For many patients, a daily pill that achieves 12-15% weight loss is preferable to a weekly injection that achieves 15-21%.
[2] Wilding JPH, et al. N Engl J Med. 2021;384(11):989-1002.
[3] Knop FK, et al. Lancet. 2023;402(10403):705-719.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsI have a pharmacology question. If orforglipron is a non-peptide small molecule, does it bind to the GLP-1 receptor in the same way as native GLP-1 and semaglutide? And does that matter for efficacy or safety?
I'm wondering if different binding modes could lead to different signaling profiles — what pharmacologists call "biased agonism." Could orforglipron have a different balance of G-protein vs beta-arrestin signaling compared to peptide GLP-1 RAs?
Excellent pharmacology question. You're right that binding mode matters. Orforglipron binds to an allosteric site on the GLP-1 receptor, distinct from the orthosteric site where native GLP-1 and semaglutide bind[4]. Despite this, it appears to be a full agonist with a signaling profile that closely mimics peptide GLP-1 RAs in terms of cAMP generation and insulin secretion.
There are subtle differences in receptor internalization and recycling kinetics. Preclinical data suggests orforglipron may cause less beta-arrestin-mediated receptor internalization than peptide agonists. In theory, this could result in less tachyphylaxis (receptor desensitization) over time — but this is speculative and unproven in humans.
From a safety perspective, the Phase 2 data showed a very similar adverse event profile to peptide GLP-1 RAs (nausea, vomiting, diarrhea as the most common). No novel safety signals. This suggests the clinical effects are mediated through the same downstream pathways.
[4] Kawai T, et al. Proc Natl Acad Sci USA. 2020;117(47):29959-29967.